Ratings Next Science Limited

Equities

NXS

AU0000041329

Market Closed - Australian S.E. Other stock markets 06:36:42 07/05/2024 BST			5-day change	1st Jan Change
0.36 ^AUD	+2.86%		+16.13%	+5.88%

05-03	Transcript : Next Science Limited - Shareholder/Analyst Call
04-24	Next Science Product Sales Rise 19% to $5.5 Million for March Quarter	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the past four months, analysts' average price target has been revised upwards significantly.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company appears highly valued given the size of its balance sheet.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
NEXT SCIENCE LIMITED	+5.88%	67.59M	-
ELI LILLY AND COMPANY	+32.86%	690B	C+
NOVO NORDISK A/S	+26.43%	546B	B
JOHNSON & JOHNSON	-4.91%	358B	C+
MERCK & CO., INC.	+18.14%	323B	B-
ABBVIE INC.	+5.04%	287B	C+
ASTRAZENECA PLC	+14.32%	235B	B+
NOVARTIS AG	+5.79%	199B	B-
ROCHE HOLDING AG	-9.49%	195B	A+
AMGEN INC.	+4.22%	161B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes